APG Asset Management N.V. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 27.3% in Q3 2025, selling over half a million shares. Despite this, positive Phase III trial results for izalontamab brengitecan in breast cancer have boosted sentiment, potentially adding over $8 billion in long-term revenue. Bristol Myers Squibb missed EPS expectations but beat revenue forecasts, setting FY2026 guidance and raising its quarterly dividend.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
APG Asset Management N.V. Trims Stock Position in Bristol Myers Squibb Company $BMY
APG Asset Management N.V. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 27.3% in Q3 2025, selling over half a million shares. Despite this, positive Phase III trial results for izalontamab brengitecan in breast cancer have boosted sentiment, potentially adding over $8 billion in long-term revenue. Bristol Myers Squibb missed EPS expectations but beat revenue forecasts, setting FY2026 guidance and raising its quarterly dividend.